146 related articles for article (PubMed ID: 20630477)
1. The effects of the synthetic cannabinoid receptor agonists, WIN55,212-2 and CP55,940, on salicylate-induced tinnitus in rats.
Zheng Y; Stiles L; Hamilton E; Smith PF; Darlington CL
Hear Res; 2010 Sep; 268(1-2):145-50. PubMed ID: 20630477
[TBL] [Abstract][Full Text] [Related]
2. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes.
Selvi E; Lorenzini S; Garcia-Gonzalez E; Maggio R; Lazzerini PE; Capecchi PL; Balistreri E; Spreafico A; Niccolini S; Pompella G; Natale MR; Guideri F; Laghi Pasini F; Galeazzi M; Marcolongo R
Clin Exp Rheumatol; 2008; 26(4):574-81. PubMed ID: 18799087
[TBL] [Abstract][Full Text] [Related]
4. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Rahn EJ; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
[TBL] [Abstract][Full Text] [Related]
5. Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice.
Nealon CM; Henderson-Redmond AN; Hale DE; Morgan DJ
Neuropharmacology; 2019 Apr; 148():151-159. PubMed ID: 30629988
[TBL] [Abstract][Full Text] [Related]
6. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
7. Effect of Cannabinoid Receptor Agonists on Isolated Rat Atria.
Maggo S; Ashton JC
J Cardiovasc Pharmacol; 2018 Oct; 72(4):191-194. PubMed ID: 30080756
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK.
Feng YJ; Li YY; Lin XH; Li K; Cao MH
World J Gastroenterol; 2016 Nov; 22(43):9515-9524. PubMed ID: 27920472
[TBL] [Abstract][Full Text] [Related]
9. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.
Pryce G; Baker D
Br J Pharmacol; 2007 Feb; 150(4):519-25. PubMed ID: 17220914
[TBL] [Abstract][Full Text] [Related]
10. Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.
Järbe TU; LeMay BJ; Halikhedkar A; Wood J; Vadivel SK; Zvonok A; Makriyannis A
Psychopharmacology (Berl); 2014 Feb; 231(3):489-500. PubMed ID: 24005529
[TBL] [Abstract][Full Text] [Related]
11. PKCepsilon regulates behavioral sensitivity, binding and tolerance to the CB1 receptor agonist WIN55,212-2.
Wallace MJ; Newton PM; McMahon T; Connolly J; Huibers A; Whistler J; Messing RO
Neuropsychopharmacology; 2009 Jun; 34(7):1733-42. PubMed ID: 19158669
[TBL] [Abstract][Full Text] [Related]
12. WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors.
Rock RB; Gekker G; Hu S; Sheng WS; Cabral GA; Martin BR; Peterson PK
J Neuroimmune Pharmacol; 2007 Jun; 2(2):178-83. PubMed ID: 18040842
[TBL] [Abstract][Full Text] [Related]
13. Blockade of dorsal hippocampal dopamine receptors inhibits state-dependent learning induced by cannabinoid receptor agonist in mice.
Zarrindast MR; Dorrani M; Lachinani R; Rezayof A
Neurosci Res; 2010 May; 67(1):25-32. PubMed ID: 20144666
[TBL] [Abstract][Full Text] [Related]
14. Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats.
Pattij T; Janssen MC; Schepers I; González-Cuevas G; de Vries TJ; Schoffelmeer AN
Psychopharmacology (Berl); 2007 Jul; 193(1):85-96. PubMed ID: 17387457
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid CB1 receptors of the dorsal hippocampus are important for induction of conditioned place preference (CPP) but do not change morphine CPP.
Zarrindast MR; Nouri M; Ahmadi S
Brain Res; 2007 Aug; 1163():130-7. PubMed ID: 17631872
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
17. Effect of acute and subchronic administration of (R)-WIN55,212-2 induced neuroprotection and anti inflammatory actions in rat retina: CB1 and CB2 receptor involvement.
Spyridakos D; Papadogkonaki S; Dionysopoulou S; Mastrodimou N; Polioudaki H; Thermos K
Neurochem Int; 2021 Jan; 142():104907. PubMed ID: 33220388
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
19. Role of intra-accumbal cannabinoid CB1 receptors in the potentiation, acquisition and expression of morphine-induced conditioned place preference.
Karimi S; Azizi P; Shamsizadeh A; Haghparast A
Behav Brain Res; 2013 Jun; 247():125-31. PubMed ID: 23523958
[TBL] [Abstract][Full Text] [Related]
20. Basolateral amygdala CB1 cannabinoid receptors mediate nicotine-induced place preference.
Hashemizadeh S; Sardari M; Rezayof A
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jun; 51():65-71. PubMed ID: 24468643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
